Genenta Science (NASDAQ:GNTA) and Iovance Biotherapeutics (NASDAQ:IOVA) Head-To-Head Contrast

Genenta Science (NASDAQ:GNTA) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Profitability

This table compares Genenta Science and Iovance Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Iovance Biotherapeutics	-451.25%	-58.43%	-45.48%

Insider and Institutional Ownership

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 12.1% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Genenta Science and Iovance Biotherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$12.60 million	N/A	N/A
Iovance Biotherapeutics	$90.86 million	27.64	-$444.04 million	($1.49)	-5.53

Genenta Science has higher earnings, but lower revenue than Iovance Biotherapeutics.

Risk and Volatility

Genenta Science has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Genenta Science and Iovance Biotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	0	0	1	0	3.00
Iovance Biotherapeutics	0	1	8	0	2.89

Genenta Science currently has a consensus target price of $25.00, suggesting a potential upside of 420.83%. Iovance Biotherapeutics has a consensus target price of $22.33, suggesting a potential upside of 171.04%. Given Genenta Science’s stronger consensus rating and higher possible upside, analysts plainly believe Genenta Science is more favorable than Iovance Biotherapeutics.

Summary

Genenta Science beats Iovance Biotherapeutics on 8 of the 11 factors compared between the two stocks.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.